Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration.


Updates from The Motley Fool

Latest updates on Ophthotech from Fool.com.


Stock Performance

OPHT vs. S&P 500 | 2 Year Performance
View Interactive OPHT Charts
Sponsored by

Key Data Points

Primary metrics and data points about Ophthotech.
Current Price: $64.24
Prev Close: $65.03
Open: $64.94
Bid: $60.00
Ask: $0.00
Day's Range: $63.36 - $65.02
52wk Range: $35.72 - $80.00
Volume: 586,952
Avg Vol 502,135
Market Cap: $2.25B
P/E (ttm): -15.19
EPS (ttm): -$4.28
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Ophthotech.
CAPS Rating 5 out of 5
 
45 Outperform
2 Underperform
CAPS All Stars
 
8 Outperform
0 Underperform

How do you think Ophthotech will perform against the market?



You pick for Ophthotech is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


Business Summary

Industry, sector and description for Ophthotech.

Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration.

  • Exchange: NASDAQ